5-Amino-1MQ regulatory status
Current status of 5-Amino-1MQ in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of 5-Amino-1MQ?
- FDA and compounding
- Not FDA approved and not an active ingredient in any approved drug. It does not appear in FDA's Category 2 list or on the 503A bulks list as of the pages current to April 2026, and it has no USP monograph, so it does not meet any of the three bulk substance criteria in section 503A. That leaves no lawful basis for a compounding pharmacy to dispense it despite its widespread marketing as a compounded capsule. It was not part of the July 2026 advisory committee review.
- WADA
- WADA prohibited
- Access path
- No lawful United States access path identified on the last verified date.
- Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
- Products labeled research use only are not lawful for human use and are not verified for identity or purity.
Full 5-Amino-1MQ page: evidence, dosing in the literature, and sources
How has the status of 5-Amino-1MQ changed over time?
No dated regulatory event has been recorded for 5-Amino-1MQ. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for 5-Amino-1MQ and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
- [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
From the blog
- 5-amino-1MQ for fat loss: mouse data, no human trials
5-amino-1MQ reduced fat mass in obese mice, but no human study of any kind has been published. What the mouse studies found, capsules vs injection, side effects, and legal status.